Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results

This animated video visually explores the distinct mechanisms of action (MOAs) of anticholinergics and VMAT-2 inhibitors in managing tardive dyskinesia. It highlights the efficacy and safety differences between the two drug classes, emphasizing how VMAT-2 inhibitors target dopamine dysregulation at the synaptic level, resulting in more targeted and effective symptom relief compared to the broader and less specific effects of anticholinergics.